Levodopa And NotAmos D. Korczyn
List of bibliographic references
Number of relevant bibliographic references: 17.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 001A50 | T. Caraceni [Italie] ; M. Musicco [Italie] | Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study |
| 001C37 | A. P Strafella [Italie] ; F. Valzania [Italie] ; S. A Nassetti [Italie] ; A. Tropeani [Italie] ; A. Bisulli [Italie] ; M. Santangelo [Italie] ; C. A Tassinari [Italie] | Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study |
| 001D26 | William J. Weiner [États-Unis] | The initial treatment of Parkinson's disease should begin with levodopa |
| 001E89 | Patriciac. Poluha [États-Unis] ; Hans-Leo Teulings [États-Unis] ; Roberth. Brookshire [États-Unis] | Handwriting and speech changes across the levodopa cycle in Parkinson’s disease |
| 001E96 | John D. O'Sullivan [Australie] ; Catherine M. Said [Australie] ; Louise C. Dillon [Australie] ; Marion Hoffman [Australie] ; Hughes [Australie] | Gait analysis in patients with Parkinson's disease and motor fluctuations: Influence of levodopa and comparison with other measures of motor function |
| 001F84 | Larsen [Norvège] ; Jette Boas [Danemark] | The effects of early selegiline therapy on long‐term levodopa treatment and parkinsonian disability: An interim analysis of a norwegian–danish 5‐year study |
| 001F94 | P. Stanzione [Italie] ; R. Traversa [Italie] ; M. Pierantozzi [Italie] ; R. Semprini [Italie] ; M. Loberti [Italie] ; A. Peppe [Italie] ; A. M. Santilli [Italie] ; G. Bernardi [Italie] | SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status |
| 002129 | J. Boas [Danemark] ; J. Worm-Petersen [Danemark] ; E. Dupont [Danemark] ; B. Mikkelsen [Danemark] ; L. Wermuth [Danemark] | The levodopa dose‐sparing capacity of pergolide compared with that of bromocriptine in an open‐label, crossover study |
| 002198 | Roos [Pays-Bas] ; J. C. F. Jongen [Pays-Bas] ; E. A. Van Der Velde [Pays-Bas] | Clinical course of patients with idiopathic Parkinson's disease |
| 002335 | Clarke [Royaume-Uni] | Does levodopa therapy delay death in Parkinson's disease? A review of the evidence |
| 002359 | Przedborski [États-Unis] ; Vernice Jackson-Lewis [États-Unis] ; Stanley Fahn [États-Unis] | Antiparkinsonian therapies and brain mitochondrial complex I activity |
| 002428 | Roberto Marconi [France, Italie] ; Dominique Lefebvre-Caparros [France] ; Anne-Marie Bonnet [France] ; Marie Vidailhet [France] ; Bruno Dubois [France] ; Agid [France] | Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology |
| 002462 | Olanow [États-Unis] ; S. Fahn [États-Unis] ; M. Muenter [États-Unis] ; H. Klawans [États-Unis] ; H. Hurtig [États-Unis] ; M. Stern [États-Unis] ; I. Shoulson [États-Unis] ; R. Kurlan [États-Unis] ; J. D. Grimes [Canada] ; Joseph Jankovic [États-Unis] ; M. Hoehn [États-Unis] ; C. H. Markham [États-Unis] ; R. Duvisin [États-Unis] ; O. Reinmuth [États-Unis] ; H. A. Leonard [États-Unis] ; E. Ahlskog [États-Unis] ; R. Feldman [États-Unis] ; L. Hershey [États-Unis] ; M. D. Yahr [États-Unis] | A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease |
| 002550 | Factor [États-Unis] ; William J. Weiner [États-Unis] | Early combination therapy with bromocriptine and levodopa in parkinson's disease |
| 002625 | María Angeles Mena ; Beatriz Pardo ; María José Casarejos ; Stanley Fahn [États-Unis] ; Justo García De Yébenes [Espagne] | Neurotoxicity of levodopa on catecholamine‐rich neurons |
| 002691 | Fabio Baronti [États-Unis] ; Katherine E. Conant [États-Unis] ; Marianne Giuffra [États-Unis] ; Thomas L. Davis [États-Unis] ; Giorgio Brughitta [États-Unis] ; Michael J. Iadarola [États-Unis] ; Wade H. Berrettini [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Opioid peptides in Parkinson's disease: effects of dopamine repletion |
| 002A04 | S. Kaakkola [Finlande] ; P. T. M Nnistö [Finlande] ; E. Nissinen [Finlande] ; A. Vuorela [Finlande] ; R. M Ntyl [Finlande] | The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa |
| This area was generated with Dilib version V0.6.23. |  |